Invention Grant
- Patent Title: Methods of treating colorectal cancer
-
Application No.: US16306290Application Date: 2017-06-02
-
Publication No.: US11332529B2Publication Date: 2022-05-17
- Inventor: Michael Axelson
- Applicant: Bristol-Myers Squibb Company
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- International Application: PCT/US2017/035822 WO 20170602
- International Announcement: WO2017/210637 WO 20171207
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; A61P35/00 ; A61K39/00

Abstract:
This disclosure provides methods for treating a tumor derived from a colorectal cancer exhibiting a high degree of microsatellite instability in a subject comprising administering to the subject an anti-PD-1 antibody. In some embodiments, the method further comprises administering an anti-CTLA-4 antibody. In some embodiments, the colorectal cancer is rectal cancer, colon cancer, or any combination thereof.
Public/Granted literature
- US20190153100A1 USE OF ANTI-PD-1 ANTIBODY IN THE TREATMENT OF PATIENTS WITH COLORECTAL CANCER Public/Granted day:2019-05-23
Information query